Uusitupa M, Tuomilehto J, Karttunen P, Wolf E
Ann Clin Res. 1984;16 Suppl 43:126-31.
A double-blind, placebo-controlled trial was carried out in 17 Type 2 (non-insulin-dependent) diabetic patients, treated with diet therapy alone to study the effects of guar gum on metabolic control, serum lipids, and blood pressure levels. Thirteen of the patients had drug treatment for hypertension. Guar gum was taken with meals three times a day, and the dose was gradually increased to 21 g per day. A slight, but not significant improvement was found in the metabolic control of the patients after the guar gum treatment compared to the placebo. Serum total cholesterol was 11% (p greater than 0.01) lower after the guar gum but no significant differences were found in HDL-cholesterol or serum triglycerides during the guar gum treatment compared to the placebo. Diastolic blood pressure level was significantly lower during the guar gum treatment compared to placebo. No difference was observed in systolic blood pressure levels between the guar gum and placebo treatments. The reduction of diastolic blood pressure was independent of changes in fasting blood glucose level or body weight, but could in part be due to simultaneous reduction in serum cholesterol concentration. The changes associated with guar gum supplementation suggest a reduction in the risk for cardiovascular complications in diabetic patients.
对17名2型（非胰岛素依赖型）糖尿病患者进行了一项双盲、安慰剂对照试验，这些患者仅接受饮食疗法，以研究瓜尔胶对代谢控制、血脂和血压水平的影响。其中13名患者接受了高血压药物治疗。瓜尔胶每日随餐服用3次，剂量逐渐增加至每日21克。与安慰剂相比，瓜尔胶治疗后患者的代谢控制有轻微但不显著的改善。瓜尔胶治疗后血清总胆固醇降低了11%（p大于0.01），但与安慰剂相比，瓜尔胶治疗期间高密度脂蛋白胆固醇或血清甘油三酯无显著差异。与安慰剂相比，瓜尔胶治疗期间舒张压水平显著降低。瓜尔胶和安慰剂治疗之间收缩压水平无差异。舒张压的降低与空腹血糖水平或体重的变化无关，但部分可能是由于血清胆固醇浓度同时降低。与补充瓜尔胶相关的变化表明糖尿病患者心血管并发症风险降低。
